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Introduction
Drug-induced liver injury (DILI) is the most frequent reason 
for drug withdrawal during early and late stages of drug develop-
ment and clinical trials as well as after drugs are approved for the 
marketplace.1 Some drugs are more likely to cause hepatic adverse 
events than others, and some may even lead to severe liver injuries. 
Development of tools for early detection of adverse effects and 
identification of drug’s toxic potential is a major challenge within 
the pharmaceutical industry and clinical medicine.2-4 The toxi-
cology and drug safety evaluation communities have made great 
efforts in developing methodologies to assess drug toxicity risks.5-7 
These large-scale efforts also intend to elucidate whether animal 
studies can be replaced with in vitro assays and if liver injuries 
in humans can be predicted using toxicogenomic data from ani-
mals. Critical Assessment of Massive Data Analysis (CAMDA)8 
organized a challenge in 2013 to assess the performance of differ-
ent analytic methods to predict the human hepatotoxic potential 
of drugs using the Japanese Toxicogenomics Project (TGP)9 data 
set. The challenge aimed to foster the development of computa-
tional approaches and to promote these within the scope of tools 
for drug toxicity estimation.
Molecular biology abounds with data from sequencing, 
expression studies, function annotations, and studies of inter-
actions between genes, proteins and drugs. These data sets are 
related, and analysis of one data set could benefit from the inclu-
sion of information from others. We have recently proposed a 
data fusion approach10 that can elegantly integrate heterogeneous 
data sets, representing each data set in a matrix and fusing the 
data sets by simultaneous matrix factorization. We here report 
on the fusion of 29 data sets from the TGP and related data 
repositories to predict DILI risk. We assess the value of combin-
ing conventional toxicogenomic data sets with circumstantial 
evidence for more informed prediction of adverse drug reactions 
and hepatotoxicity. We compare the accuracy of data fusion to 
that of a standard multi-classifier approach where we stack four 
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Traditional studies of liver toxicity involve screening compounds through in vivo and in vitro tests. They need to dis-
tinguish between compounds that represent little or no health concern and those with the greatest likelihood to cause 
adverse effects in humans. high-throughput and toxicogenomic screening methods coupled with a plethora of circum-
stantial evidence provide a challenge for improved toxicity prediction and require appropriate computational methods 
that integrate various biological, chemical and toxicological data. We report on a data fusion approach for prediction of 
drug-induced liver injury potential in humans using microarray data from the Japanese Toxicogenomics Project (TGP) as 
provided for the contest by caMDa 2013 conference. Our aim was to investigate if the data from different TGP studies 
could be fused together to boost prediction accuracy. We were also interested if in vitro studies provided sufficient infor-
mation to refrain from studies in animals. We show that our recently proposed matrix factorization-based data fusion 
provides an elegant computational framework for integration of the TGP and related data sets, 29 data sets in total. 
Fusion yields a high cross-validated accuracy (aUc of 0.819 for in vivo assays), which is above the accuracy of the estab-
lished machine learning procedure of stacked classification with feature selection. Our data analysis shows that animal 
studies may be replaced with in vitro assays (aUc = 0.799) and that liver injury in humans can be predicted from animal 
data (aUc = 0.811). Our principal contribution is a demonstration that analysis of toxicogenomic data can substantially 
benefit from data fusion with directly and circumstantially related data sets.
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state-of-the-art classification algorithms. We additionally inves-
tigate feature subset selection by CUR matrix decomposition 
applied before combining classifiers with stacking.
Results
Predictive performance of a multi-classifier approach with 
feature selection
Our first experiment focused on a multi-classifier approach to 
predict DILI risk from the preprocessed TGP microarray data. 
In particular, we used stacked generalization11 to combine pre-
dictions of random forests,12 gradient boosting trees,13 logistic 
regression and support vector machines14 (Table 1). We applied 
gene filtering to perform feature selection and to identify genes 
with high statistical leverage. For that we applied the CUR 
matrix decomposition15 of the TGP microarray data sets for gene 
subset selection. CUR decomposition computes leverage scores 
for matrix columns (i.e., genes) and uses them for weighted col-
umn sampling, preferring those columns with a larger score, to 
assemble a low-dimensional matrix decomposition. Statistical 
leverage scores capture the influence of genes on the best low-
rank fit of gene expression matrix. Thus, the columns selected by 
decomposition of the microarray data defined the reduced set of 
considered genes. Table 2 shows the top ten genes with highest 
normalized statistical leverage as computed separately from ani-
mal in vitro and in vivo data.
Predictive performance of a data fusion approach
We used data fusion by matrix factorization10 to integrate vari-
ous data sets. Data sets were represented as matrices, each relating 
objects of two types. We considered objects such as genes, gene 
ontology (GO) terms, drugs, and tissue samples. For instance, 
genes and tissue samples from rat in vivo single study were related 
through corresponding gene expression data matrix. Genes and 
drugs were related through a matrix of drug targets. All together, 
we considered 29 data sets that provided relations between 14 
object types (Fig. 1). Data fusion simultaneously considers all 
data sets (relations) in the factorization schema and factorizes 
them into products of low-dimensional matrix factors, such that 
matrix factors are shared between relations that describe objects 
of the same type. Inferred latent data representation is then uti-
lized for the prediction of DILI potential of new drugs, previ-
ously unseen by the data fusion system. Our target relation in 
this system was drugs’ DILI potential, which described various 
degrees of drug toxicity. Toxicity was provided for 101 drugs and 
expressed as severe, moderate or mild. In a cross-validation study, 
a subset of considered drugs was excluded to serve for testing of 
predictions of the data fusion model developed from remaining 
drugs and all other data sets in the factorization schema. In par-
ticular, given latent matrix factors inferred from the training data 
and a new drug, we estimated drug’s latent profile by transform-
ing available relations about it to inferred latent space and then 
used the estimated profile to predict the target relation, namely 
drug’s DILI potential.10 In that way, we avoided the unwanted 
information flow between the training and test sets. Table 3 
shows the 10-fold cross-validated accuracy for seven data fusion 
scenarios that considered various data sets of the complete fusion 
model from Figure 1. The model inferred from all four TGP 
studies used all available data sets. Other models considered only 
selected toxicogenomic studies and associated non-expression 
data. For instance, fusion of in vivo assays omitted all data sets 
from in vitro studies (object types 3, 4, 7, and 8 in Fig. 1).
Influence of circumstantial evidence on the quality of the 
fused model
We estimated the effect of circumstantial data (gene annota-
tions, drug structural information, hematology data and sam-
ple metadata) on the quality of the fused factorized model. We 
observed the reconstruction quality of the target data set, which 
related drugs to DILI risk, through explained variance (Evar) and 
residual sum of squares (RSS). Better models have high Evar and 
low RSS. The influence of a data set was determined by observ-
ing the change in reconstruction quality of the target relation 
when this data set was excluded from training. Reconstruction 
of relation of DILI potential achieved Evar of 0.911 and RSS 
Table 1. Predictive performance of the multi-classifier approach for DILI potential prediction with and without cUR feature subset selection (Fss)
Multi-classifier system
Human in vitro Rat in vitro
Rat in vivo 
single dose
Rat in vivo 
repeated doseFss stacking with LR
Pca RF, GBT, LR, sVM 0.741 0.765 0.748 0.761
cUR RF, GBT, LR, sVM 0.758 0.755 0.764 0.778
10-fold cross-validated aUc scores are reported. RF, random forests;12 GBT, gradient boosting trees;13 LR, logistic regression; sVM, support vector 
machine (polynomial third degree kernel); Pca, principal component analysis.
Table 2. Genes with the highest influence on the fit of low-rank cUR 
decomposition of rat in vitro and rat in vivo expression data
Rat in vitro Rat in vivo, single dose
Gene symbol
Leverage 
scorehest
Gene symbol Leverage score
cyp1a1 0.671 Fam111a 0.972
angptl4 0.121 RGD1309362 0.953
cyp4a3 0.119 aldh1a7 0.919
Gdf15 0.086 ephx2 0.906
chac1 0.086 Ubd 0.873
ctgf 0.084 Ilf3 0.735
acta1 0.080 Ifit1 0.714
hmgcs2 0.079 hamp 0.664
G0s2 0.075 akr1c12 0.565
ccl20 0.074 RT1-Bb 0.492
higher values indicate the higher statistical leverage of a gene. 
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of 8.779 in 10-fold cross-validated study when the entire collec-
tion of data sets was considered. This quality decreased by 1.0% 
in Evar and 11.7% in RSS when omitting the data on hematol-
ogy, biochemistry and liver weight (type 12; Fig. 1) from the 
entire collection of data sets. In contrast, we observed a 9.6% 
decrease in Evar and a 12.8% increase in RSS when excluding 
sample metadata (type 9; Fig. 1) from the collection, and a 0.7% 
decrease in Evar and 9.4% increase in RSS without considering 
related drug data (type 11; Fig. 1) in the fusion. Exclusion of 
gene annotations (type 13; Fig. 1) slightly worsened the fused 
model with respect to Evar (a decrease of 0.2%) but improved 
the RSS by 0.3%.
Figure 1. The fusion configuration for drug-induced liver injury prediction. Nodes represent 14 object types. arcs denote data sets that relate objects 
of different types (relation matrices, Ri,j) or objects of the same type (constraints, Θi,i) for a total of 29 matrices (data sets). The bold arc (R10,14, R14,10 = 
RT10,14) represents relation between drugs and DILI potential that we try to augment. Fused data sets include gene annotations that are encoded in {0, 
1}-matrices (R1,13, R2,13, R3,13, R4,13); expression profiles (R1,5, R2,6, R3,7, R4,8); hematology, body weight and clinical chemistry data for each rat (R5,12, R6,12, R12,5 = 
RT5,12, R12,6 = R
T
6,12); array metadata information such as dose level, dosage time and sacrifice time (R5,9, R6,9, R7,9, R8,9, R9,5 = R
T
5,9, R9,6 = R
T
6,9, R9,7 = R
T
7,9, R9,8 = 
RT8,9); drug targets (R1,10, R2,10, R3,10, R4,10); indication of medical drugs tested with samples (R5,10, R6,10, R7,10, R8,10) and structure and categorization of drugs 
(R10,11, R11,10 = R
T
10,11). constraint matrices encode protein-protein interactions (Θ1,1, Θ2,2, Θ3,3, Θ4,4), drug interactions (Θ10,10) and the semantic structure of 
the Gene Ontology graph (Θ13,13).
e28527-4 systems Biomedicine Volume 2 
Discussion
From a computational perspective, the contributions of our 
work presented in this manuscript are 2-fold. First, we evaluated 
the performance of CUR matrix decomposition to select genes 
that exhibited high statistical leverage and employed a reduced 
data set using well-established classification ensemble methods. 
Second, we pursued a novel data fusion approach based on matrix 
factorization to assess the hepatotoxic risk associated with indi-
vidual drugs by fusing gene expression profiles with a plethora of 
related and heterogeneous data sets.
In our first experiment, we considered the DILI prediction 
problem for each toxicogenomic study separately and pursued a 
multi-classifier approach (Table 1). The training data consisted of 
microarray profiles (independent variables) and associated drugs 
with given DILI potentials (dependent variable). Feature subset 
selection was performed independently on the training data from 
each fold of cross-validation and features selected by CUR matrix 
decomposition or constructed by PCA were then used to assess the 
classifier’s performance on test data. Feature subset selection by 
CUR matrix decomposition substantially reduced the number of 
input features. For instance, and as averaged across folds of cross-
validation, a subset of only about 300 genes was used for training 
the prediction models in the human in vitro study instead of the 
original 18,988 genes included by the FARMS16 summarization. 
The solid performance of multi-classifier approach was not sur-
prising17,18 as several previous studies19,20 on this data have already 
reported good results with single classification algorithms such 
as support vector machines or gradient boosting. In our case, the 
performance was boosted by both feature selection and classifier 
ensembling. Also of note is the comparable performance of data 
preprocessing by CUR decomposition and principal component 
analysis (PCA). As CUR performs feature selection rather than 
feature transformation, it could be a preferable procedure to iden-
tify gene biomarkers (Table 2).
Results in Table 1 show that using repeated dose studies (rat, 
in vivo repeated dose) when forecasting the toxic potency of com-
pounds in humans yielded more accurate models than employing 
single dose animal studies (rat, in vivo single dose). According to 
Greim et al.21 and Blaauboer and Andersen,22 repeated dose stud-
ies in animals represent critical data for hazard identification and 
risk assessment in humans. They claimed that the 28-d toxicity 
study, which was also used by the TGP, is the minimum require-
ment to evaluate the organ specific effects of compounds. Our 
results of the multi-classifier approach show that in the absence 
of such information the assessment of continuous human expo-
sure to hazardous compounds is incomplete.
For an integrative approach that simultaneously considered 
all available experimental and circumstantial data, we used data 
fusion by matrix factorization,10 an intermediate data integration 
approach that is able to fuse heterogeneous data sets. Intermediate 
integration is often the preferred integration strategy23-25 as it 
embeds the structure of the data into a predictive model and thus 
often achieves higher accuracy. Data fusion surpassed the accu-
racy of the multi-classifier approach for predicting DILI poten-
tial in humans (Table 3). The most accurate model was inferred 
by fusing in vivo assays, which scored an AUC of 0.819. It is 
surprising that in vivo assays, which relied on an animal model, 
performed better than human assays, given the aim was to pre-
dict DILI potential in humans. However, Pessiot et al.19 similarly 
observed that using in vivo animal data was more informative 
than using in vitro human data. Their AUC scores obtained by a 
linear support vector machine classifier and inferred from sepa-
rate toxicogenomic studies were surpassed by those reported by 
our fusion-based approach.
The fusion-based model inferred from animal assays (two 
in vivo studies and one in vitro study) outperformed the model 
obtained by fusing human assays only (one human in vitro study), 
with the first achieving an AUC of 0.811 and the latter an AUC 
of 0.792. One might expect that the administration of drugs 
to animal models would fail to identify the risk of liver injury 
for drugs prescribed to humans due to differences in metabolic 
pathways and the current lack of suitable animal models that can 
reproduce human risk factors.4 Our results do not confirm this 
hypothesis; however, differences in performance are small and 
further investigations seem worthwhile.
The study of influence of data sets on the reconstruction qual-
ity of target relation between drugs and DILI risk (see Results) 
showed that, though some data sets were small in their size, 
they substantially affected reconstruction of target relation. For 
example, sample metadata included only seven features, such as 
information about animal sacrifice period and dose level, yet its 
exclusion from data fusion resulted in a near 10% decrease in 
reconstruction quality of target relation. In contrast, we observed 
only a slight reduction in model quality when gene annotation 
data were omitted from the fused model despite annotation data 
recording associations to more than 7,000 GO terms.
Although gene expression profiling is an accepted approach for 
identifying drugs with potential safety problems,9 our results sug-
gest that integrating expression profiles with circumstantial data 
on drugs, arrays and genes can further improve predictive perfor-
mance of analytic approaches and pinpoint the mechanisms that 
underlie drug toxicity. Our data fusion approach should be appli-
cable to other toxicity endpoints, such as neurotoxicity, or mecha-
nisms of action, such as regenerative hyperplasia. We anticipate 
that efforts in data analysis hold the promise to replace animal 
studies with in vitro assays and predict the outcome of liver inju-
ries in humans using in vitro animal toxicogenomic data.
Table 3. Predictive performance of fusing various subsets of assays for DILI 
potential prediction
Data fusion studies AUC
In vivo studies 0.819
In vitro studies 0.790
human in vitro study 0.793
animal in vitro study 0.799
animal studies 0.811
human studies 0.792
all studies 0.810
10-fold cross-validated aUc scores are reported.
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Materials and Methods
Data collections
We performed two computational experiments, one with 
a multi-classifier and the other with a data fusion approach. 
The multi-classifier approach considered gene expression data 
sets provided by the Japanese Toxicogenomics Project (TGP), 
which consisted of two in vivo studies (performed on rat cell 
lines) and two in vitro studies (one performed on rat and one 
on human cell lines). In addition to gene expression data, the 
data fusion approach also included data on drugs available from 
DrugBank (http://www.drugbank.ca), gene annotations from 
Gene Ontology (http://www.geneontology.org), protein–protein 
interactions from STRING (http://string-db.org), and hemato-
logical and clinical chemistry data for each animal and sample 
metadata information. Data fusion considered 14 types of objects 
(nodes in Fig. 1, e.g., genes, GO terms, or drugs) and a collection 
of 29 data sets, each relating a pair of object types (arcs in Fig. 1, 
e.g., gene annotations that relate genes and GO terms). We rep-
resented observations from a data source that related two distinct 
object types i and j in a sparse relation matrix R
i,j
. For example, 
the matrix R
1,13
 encoded the annotations of genes from the rat 
in vivo single dose study. A data source that provided relations 
between objects of the same type i was represented by a con-
straint matrix Θ
i,i
 (e.g., Θ
10,10
 for DrugBank’s drug interactions).
Gene expression data and sample metadata
The TGP9 created a gene expression database using the 
Affymetrix GeneChip arrays to measure the effects of 131 
chemicals, mainly medical drugs, on the liver. Approximately 
20,000 samples (tissue/drug combinations) were studied both 
in vivo and in vitro. The in vivo study used the rat as a model 
organism and considered two experimental designs: a single dose 
study, consisting of multiple time points with multiple dose levels 
and a repeated dose study, consisting of multiple dose periods 
with multiple dose levels. The probe level intensity ratios were 
quantile-normalized, corrected for chemical batch effects and 
summarized using FARMS technique16 to obtain expression val-
ues per genes.26 Replicate measurements were collapsed to one 
measurement per gene, which resulted in 12,088 rat genes and 
18,988 human genes. We removed samples whose correspond-
ing chemicals were not annotated with human DILI potential 
and retained 4,824 samples from the rat in vivo single dose study 
(R
1,5
), 4,827 samples from the rat in vivo repeated dose study 
(R
2,6
), 2,424 samples from the rat in vitro study (R
3,7
) and 1,116 
samples from the human in vitro study (R
4,8
). For each sample we 
considered seven metadata features (R
5,9
, R
6,9
, R
7,9
, R
8,9
), includ-
ing animal sacrifice period, dose and dose level, animal age in 
weeks and sex type.
Histological and clinical chemistry data
Data obtained for each animal in single dose and repeated 
dose TGP studies included histopathology, animal weight, food 
consumption, hematology and blood chemistry. For each animal 
sample we included 41 attributes (R
5,12
, R
6,12
) describing hematol-
ogy, such as the levels of monocytes and lymphocytes, biochemis-
try, such as the concentration of albumin (RALB), direct bilirubin 
(DBIL) and total bilirubin (TBIL), and body and liver weight.
Drug data
We obtained drug information data from the DrugBank27 
database. We related drugs to their gene targets (binary matri-
ces R
1,10
, R
2,10
, R
3,10
, R
4,10
) and assigned structural groups (binary 
matrix R
10,11
). We considered joint adverse effects of drug pairs 
and DILI risk class co-membership of drugs and included them 
in the training set (Θ
10,10
). A constraint between a pair of drugs 
was set to (−1)ck/10−3, where k was the number of joint adverse 
effects of a drug pair and c indicated if the two drugs belonged 
to the same class of DILI risk. The DILI severity in humans was 
determined for 101 out of 131 drugs based on FDA-approved 
drug labeling.2 Each drug was assigned to one of three categories 
resulting in 41 drugs of severe DILI concern, 51 drugs of moder-
ate DILI concern and 8 drugs of mild or no DILI concern.
Protein–protein interaction data
We included protein–protein interactions from the STRING28 
database as constraints between corresponding genes. Degrees of 
interaction were represented with STRING confidence scores 
and used to populate constraint matrices, Θ
1,1
, Θ
2,2
, Θ
3,3
, Θ
4,4
.
Gene Ontology data
We considered gene annotations from Gene Ontology (GO).29 
We extracted 7,056 GO terms to populate binary relation matri-
ces R
1,13
, R
2,13
, and R
3,13
 with 169,816 rat gene annotations and 
matrix R
4,13
 with 288,764 human gene annotations. The hierar-
chical structure of GO (Θ
13,13
) was included by reasoning over 
has_part, part_of and is_a relations in the GO graph. A con-
straint between a pair of GO terms was set to -0.2hops, where hops 
was the length of the shortest path between the two GO terms.
Data fusion by matrix factorization
We applied data fusion to infer relation between drugs and 
DILI potential. This relation, encoded in target matrix R
10,14
, was 
observed in the context of all other data sets. Matrix  
was a [0, 1]-matrix that was only partially observed. Its entries 
indicated the degree of membership of drugs to the three DILI 
severity classes. Our data fusion approach involves three main 
steps.10 First, data are encoded in constraint and relations matri-
ces and organized in a block-based matrix representation. In the 
second step, relation matrices R
i,j
 are simultaneously tri-factor-
ized given constraints in Θ
i,i
. Every relation matrix is decom-
posed into a product of three low-rank matrix factors, such that a 
relation matrix R
i,j
 is approximated by .
Constraint matrices serve to regularize the low-rank approxi-
mations of relation matrices. The key idea of data fusion is the 
sharing of low-rank matrix factors between relation matrices that 
describe objects of common type. For instance, the latent matrix 
factor of drugs, G
10
, is shared between decompositions of all rela-
tion matrices in Figure 1 whose arcs point to a drug node but 
the matrix factor S
7,10
 is used only in reconstruction of the corre-
sponding relation matrix between in vitro samples performed on 
rat cell lines and drugs. The resulting fused system contains fac-
tors S
i,j
 that are specific to every relation matrix (data source) and 
factors G
i
 that are specific to every object type. Thus, low-rank 
matrix factors S
i,j
 and G
i
 capture source- and object type-specific 
patterns, respectively. Finally, we use matrix factors to complete 
unobserved entries in relation matrices and to transform new 
objects to the fused latent space. We refer the reader to Žitnik 
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and Zupan10 for the derivation of factorization model and fur-
ther details on computing the factorization and prediction from 
low-rank matrix factors. In this study, we aimed to predict the 
unobserved entries in R
10,14
. The DILI severity of d-th drug was 
determined as .
Predictions for d-th drug in the binary classification problem 
of severe DILI risk against moderate or mild DILI risks were esti-
mated by .
Related matrix factorization approaches
Matrix factorization algorithms are a popular class of data 
analysis methods and are often used for dimensionality reduc-
tion, clustering or low-rank approximation. For example, 
Hochreiter et al.30 proposed a factorization-inspired Bayesian 
approach for biclustering of transcriptomic data. In particular, 
nonnegative matrix factorization (NMF) algorithms, which 
impose the nonnegativity constraints on latent matrix factors, 
and their various generalizations became widely used in bioin-
formatics. We refer the reader to Wang and Zhang31 for a com-
prehensive review of basic NMF algorithms and their existing 
modifications that can incorporate additional constraints, such 
as orthogonality, sparseness and preservation of local topologi-
cal properties, through regularization. The approach used in this 
study is conceptually different from those techniques. It modifies 
the standard factorization formulation such that it can consider 
multi-relational and multi object-type data without necessitating 
substantial data transformation. In this way it breaks through the 
conventional feature-based data types and factorization of single 
dyadic relation. Few existing matrix factorization approaches for 
data integration (see Žitnik and Zupan10 and references therein) 
can model multiple relations between the same two sets of objects 
(e.g., genes and drugs) or can vary object types along one dimen-
sion of data matrices. They would often require full set of pair-
wise relations between all pairs of object types. On the contrary, 
our approach can model multiple relations between multiple 
object types without imposing assumptions about matrix struc-
tural properties.
Multi-classifier approach and feature subset selection by 
CUR matrix decomposition
We employed CUR matrix decomposition15 to identify a small 
set of information carrying genes. CUR matrix decomposition 
approximates target matrix A in an unsupervised manner as A 
≈ CUR, where C and R are low-dimensional matrix factors that 
contain a subset of columns and rows from A, respectively. The 
advantage of CUR decomposition over some well-known low-
rank matrix decompositions such as principal component analy-
sis (PCA) or singular value decomposition (SVD) is its explicit 
representation in terms of a small number of actual columns and 
rows of target data matrix. The CUR decomposition-selected fea-
tures corresponded to original gene expression profiles instead of 
their linear combinations as with PCA and SVD. We performed 
feature subset selection solely on the training set and trans-
formed the test data to reduced feature space as defined by CUR 
decomposition or PCA. We then applied several state-of-the-art 
classifiers to predict the DILI concern in humans from the matrix 
factor C obtained for each toxicogenomic study separately. We 
used gradient tree boosting,13 random forests12 and a support vec-
tor machine14 with polynomial kernel to predict drug-induced 
toxicity. Output class probabilities generated by the classifiers 
were combined through stacking to compensate for classifier 
biases.11 Stacking took as input predicted class probabilities and 
generalized over them with logistic regression, which increased 
the accuracy of the best of the individual classifiers, reduced the 
variance and prevented overfitting. It was shown that relatively 
global and simple combiners that can avoid overfitting on highly 
correlated input models often produce most accurate results.17,32
Experimental setup
The performance of above described modeling techniques and 
fusion scenarios was assessed through 10-fold cross-validation 
and evaluated with the area under the receiver operating char-
acteristic curve (AUC). The AUC score represents the probabil-
ity that, given a pair of randomly drawn drugs from the positive 
and negative classes, respectively, the predictor ranks the positive 
drug higher than the negative drug in terms of being “positive.” 
The AUC is robust to class imbalance and is not biased against 
minority class.33 In the multi-classifier approach, we considered 
the problem of predicting drug-induced toxicity as a binary clas-
sification of severe DILI concern against moderate or mild DILI 
potential. In order to compare the performance of data fusion to 
multi-classifier approach we casted predictions made by fusion 
into a binary problem as was done for the multi-classifier experi-
ments. Feature subset selection for the multi-classifier approach 
was performed within cross-validation on a training data set. 
Parameters of the classification algorithms, such as the number 
of iterations and the sizes of the constituent trees in gradient 
boosting trees, the penalty parameter in support vector machine 
and the regularization term in logistic regression, were estimated 
through internal cross-validation on the training data. The 
matrix decomposition algorithm used by data fusion required a 
14-tuple of factorization ranks, one value per object type, which 
were selected from a predefined range of values by estimating the 
quality of low-rank fit of target matrix  using explained vari-
ance (Evar) and residual sum of squares (RSS). Initial values of 
matrix factors were set uniformly at random. The algorithm ter-
minated when the improvement in convergence of target matrix 
approximation between consecutive iterations measured as the 
Frobenius distance was below 1 × 10−5.
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